SK Chemical recently received sales approval of the treatment of rare diseases 'Replagal inj’
On August 25, according to the related industry, SK Chemical recently received sales approval of the treatment of rare diseases 'Replagal inj (α-galactosidase A)' from the Minister of Food and Drug Safety.
Replagal is the treatment with long-term enzyme replacement therapy indicated for patients...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
